Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
Candida infective endocarditis is a rare disease with a high mortality rate. Our understanding of this infection is derived from case series, case reports, and small prospective cohorts. The purpose of this study was to evaluate the clinical features and use of different antifungal treatment regimens for Candida infective endocarditis. This prospective cohort study was based on 70 cases of Candida infective endocarditis from the International Collaboration on Endocarditis (ICE)-Prospective Cohort Study and ICE-Plus databases collected between 2000 and 2010. The majority of infections were acquired nosocomially (67%). Congestive heart failure (24%), prosthetic heart valve (46%), and previous infective endocarditis (26%) were common comorbidities. Overall mortality was high, with 36% mortality in the hospital and 59% at 1 year. On univariate analysis, older age, heart failure at baseline, persistent candidemia, nosocomial acquisition, heart failure as a complication, and intracardiac abscess were associated with higher mortality. Mortality was not affected by use of surgical therapy or choice of antifungal agent. A subgroup analysis was performed on 33 patients for whom specific antifungal therapy information was available. In this subgroup, 11 patients received amphotericin B-based therapy and 14 received echinocandin-based therapy. Despite a higher percentage of older patients and nosocomial infection in the echinocandin group, mortality rates were similar between the two groups. In conclusion, Candida infective endocarditis is associated with a high mortality rate that was not impacted by choice of antifungal therapy or by adjunctive surgical intervention. Additionally, echinocandin therapy was as effective as amphotericin B-based therapy in the small subgroup analysis.
Candida infective endocarditis: An observational cohort study with a focus on therapy
Arnold C. J.;Johnson M.;Bayer A. S.;Bradley S.;Giannitsioti E.;Miro J. M.;Tornos P.;Tattevin P.;Strahilevitz J.;Spelman D.;Athan E.;Nacinovich F.;Fortes C. Q.;Lamas C.;Barsic B.;Fernandez-Hidalgo N.;Munoz P.;Chu V. H.;Clara L.;Sanchez M.;Casabe J.;Cortes C.;Oses P. F.;Ronderos R.;Sucari A.;Thierer J.;Altclas J.;Kogan S.;Harris O.;Kennedy K.;Tan R.;Gordon D.;Papanicolas L.;Korman T.;Kotsanas D.;Dever R.;Jones P.;Konecny P.;Lawrence R.;Rees D.;Ryan S.;Feneley M. P.;Harkness J.;Post J.;Reinbott P.;Gattringer R.;Wiesbauer F.;Andrade A. R.;De Brito A. C. P.;Guimaraes A. C.;Grinberg M.;Mansur A. J.;Siciliano R. F.;Strabelli T. M. V.;Vieira M. L. C.;De Medeiros Tranchesi R. A.;Paiva M. G.;Fortes C. Q.;De Oliveira Ramos A.;Weksler C.;Ferraiuoli G.;Golebiovski W.;Karlowsky J. A.;Keynan Y.;Morris A. M.;Rubinstein E.;Jones S. B.;Garcia P.;Cereceda M.;Fica A.;Mella R. M.;Fernandez R.;Franco L.;Gonzalez J.;Jaramillo A. N.;Bukovski S.;Krajinovic V.;Pangercic A.;Rudez I.;Vincelj J.;Freiberger T.;Pol J.;Zaloudikova B.;Ashour Z.;Kholy A. E.;Mishaal M.;Osama D.;Rizk H.;Aissa N.;Alauzet C.;Alla F.;Campagnac C.;Doco-Lecompte T.;Selton-Suty C.;Casalta J. -P.;Fournier P. -E.;Habib G.;Raoult D.;Thuny F.;Delahaye F.;Delahaye A.;Vandenesch F.;Donal E.;Donnio P. Y.;Flecher E.;Michelet C.;Revest M.;Chevalier F.;Jeu A.;Remadi J. P.;Rusinaru D.;Tribouilloy C.;Bernard Y.;Chirouze C.;Hoen B.;Leroy J.;Plesiat P.;Naber C.;Neuerburg C.;Mazaheri B.;Helen G.;Sofia A.;Ioannis D.;Thomas T.;Mylona E.;Paniara O.;Papanicolaou K.;Pyros J.;Skoutelis A.;Sharma G.;Francis J.;Nair L.;Thomas V.;Venugopal K.;Hannan M. M.;Hurley J. P.;Cahan A.;Gilon D.;Israel S.;Korem M.;Durante-Mangoni E.;Mattucci I.;Pinto D.;Agrusta F.;Senese A.;Ragone E.;Utili R.;Cecchi E.;De Rosa F.;Forno D.;Imazio M.;Trinchero R.;Grossi P.;Lattanzio M.;Toniolo A.;Goglio A.;Raglio A.;Ravasio V.;Rizzi M.;Suter F.;Carosi G.;Magri S.;Signorini L.;Kanafani Z.;Kanj S. S.;Sharif-Yakan A.;Abidin I.;Tamin S. S.;Martinez E. R.;Nieto G. I. S.;Van Der Meer J. T. M.;Chambers S.;Holland D.;Morris A.;Raymond N.;Read K.;Murdoch D. R.;Dragulescu S.;Ionac A.;Mornos C.;Butkevich O. M.;Chipigina N.;Kirill O.;Vadim K.;Vinogradova T.;Edathodu J.;Halim M.;Liew Y. -Y.;Tan R. -S.;Lejko-Zupanc T.;Logar M.;Mueller-Premru M.;Commerford P.;Commerford A.;Deetlefs E.;Hansa C.;Ntsekhe M.;Almela M.;Armero Y.;Azqueta M.;Castaneda X.;Cervera C.;Falces C.;Garcia-De-La-Maria C.;Fita G.;Gatell J. M.;Heras M.;Llopis J.;Marco F.;Mestres C. A.;Moreno A.;Ninot S.;Pare C.;Pericas J. M.;Ramirez J.;Rovira I.;Sitges M.;Anguera I.;Font B.;Guma J. R.;Bermejo J.;Bouza E.;Leoni M. E. G.;Robles J. A. G.;Ramallo V. G.;Cruz A. F.;Kestler M.;Marin M.;Selles M. M.;Abella H. R.;Roda J. R.;Lopez R. A.;Pinilla B.;Pinto A.;Valerio M.;Vazquez P.;Verde E.;Almirante B.;De Alarcon A.;Parra R.;Alestig E.;Johansson M.;Olaison L.;Snygg-Martin U.;Pachirat O.;Pachirat P.;Pussadhamma B.;Senthong V.;Casey A.;Elliott T.;Lambert P.;Watkin R.;Eyton C.;Klein J. L.;Kauffman C.;Bedimo R.;Corey G. R.;Crowley A. L.;Douglas P.;Drew L.;Fowler V. G.;Holland T.;Lalani T.;Mudrick D.;Samad Z.;Sexton D.;Stryjewski M.;Wang A.;Woods C. W.;Lerakis S.;Cantey R.;Steed L.;Wray D.;Dickerman S. A.;Bonilla H.;DiPersio J.;Salstrom S. -J.;Baddley J.;Patel M.;Peterson G.;Stancoven A.;Levine D.;Riddle J.;Rybak M.;Cabell C. H.;Baloch K.;Dixon C. C.;Harding T.;Jones-Richmond M.;Park L. P.;Sanderford B.;Stafford J.;Anstrom K.;Karchmer A. W.;Durack D. T.;Eykyn S.;Moreillon P.
2015-01-01
Abstract
Candida infective endocarditis is a rare disease with a high mortality rate. Our understanding of this infection is derived from case series, case reports, and small prospective cohorts. The purpose of this study was to evaluate the clinical features and use of different antifungal treatment regimens for Candida infective endocarditis. This prospective cohort study was based on 70 cases of Candida infective endocarditis from the International Collaboration on Endocarditis (ICE)-Prospective Cohort Study and ICE-Plus databases collected between 2000 and 2010. The majority of infections were acquired nosocomially (67%). Congestive heart failure (24%), prosthetic heart valve (46%), and previous infective endocarditis (26%) were common comorbidities. Overall mortality was high, with 36% mortality in the hospital and 59% at 1 year. On univariate analysis, older age, heart failure at baseline, persistent candidemia, nosocomial acquisition, heart failure as a complication, and intracardiac abscess were associated with higher mortality. Mortality was not affected by use of surgical therapy or choice of antifungal agent. A subgroup analysis was performed on 33 patients for whom specific antifungal therapy information was available. In this subgroup, 11 patients received amphotericin B-based therapy and 14 received echinocandin-based therapy. Despite a higher percentage of older patients and nosocomial infection in the echinocandin group, mortality rates were similar between the two groups. In conclusion, Candida infective endocarditis is associated with a high mortality rate that was not impacted by choice of antifungal therapy or by adjunctive surgical intervention. Additionally, echinocandin therapy was as effective as amphotericin B-based therapy in the small subgroup analysis.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11390/1326860
Citazioni
ND
96
ND
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.